Orthofix (Nasdaq: OFIX) + today announced plans to present new data supporting the use of its proprietary pulsed electromagnetic field (PEMF) stimulation.

Lewisville, Texas-based Orthofix is evaluating PEMF stimulation to increase fusion rates as an adjunct to lumbar spine fusion surgery. Patients treated with the SpinalStim bone growth therapy demonstrated a high rate of successful fusion, according to a news release. The company also reported significant improvements in pain, function and quality of life, despite having risk factors for pseudarthrosis.

Dr. Marc Weinstein, an orthopedic spine surgeon at the Florida Orthopaedic Institute in Tampa, Florida, will present an abstract on SpinalStim. The presentation takes place on Sept. 25 at the North American Spine Society (NASS) Annual Meeting in Chicago.

Orthofix also plans to highlight a variety of new products, including a full market launch for its OsteoStrand Plus C. The 100% bone-derived graft features demineralized bone matrix (DBM) fibers and Accell bone matrix. This dispersed form of DBM provides the immediate release of growth factors upon implantation. It also increases the concentration of growth factors in the product, and cancellous chips.

The company also plans to launch its M6-C single-use, disposable instrumentation sets. Orthofix designed the FDA-cleared instruments specifically for cervical disc arthroplasty.